Science - USA (2022-05-27)

(Maropa) #1

Tanget al., Science 376 , eabe1505 (2022) 27 May 2022 2of13


Feature
Promoter (<=1kb)

5' UTR

1st Exon
Other Exon
1st Intron
Other Intron
Do
Distal Intergenic

Feature Distribution

MSK
organoids

WCM
organoids

Cell lines

PDX

PARCB8
PARCB6P

MSKEF1PARCB1

PDX16bPDX16a

VCaP
LNCaP

WCM155

MSKPCa18

MSKPCa16
MSKPCa15

MSKPCa11

MSKPCa8

MSKPCa1

Percentage(%)

1 2 3 4 5 6 7 8 9 10 11 12 13 141516171819202122 X
SU2C Patients

MSKPCa8
MSKPCa9
MSKPCa10
MSKPCa11
MSKPCa12
MSKPCa13
MSKPCa14MSKPCa15
MSKPCa16MSKPCa17
MSKPCa18
MSKPCa19
MSKPCa20
MSKPCa22MSKPCa24
PDX01aPDX09a
PDX16a/bPDX10a
PDX34a

MSKPCa/PDX

Sample type: Organoid Organoid only Tissue

C D

EF

A

AR

MSKPCa1MSKPCa2MSKPCa3MSKPCa8MSKPCa9MSKPCa10MSKPCa11MSKPCa12MSKPCa13MSKPCa14MSKPCa15MSKPCa16MSKPCa17

SYP
GAPDH

LNCaPVCaP22Rv1
C4-2PC3
DU145H660
WCM154WCM155WCM1078WCM1262

MSKPCa18MSKPCa19MSKPCa20MSKPCa22MSKPCa24

PDX01aPDX09aPDX10aPDX16aPDX16bPDX34a

AR
SYP
GAPDH

AR
SYP
GAPDH

ATAC-seq group
Group 1
Group 2
Group 3
Group 4

AR expression
AR high
AR low
AR neg

0 2 4 6
UMAP-1

0

2

UMAP-2

PDX34a

MSKPCa8

DU145

MSKPCa22

PDX01a

WCM154

MSKPCa20

MSKPCa14

MSKPCa10

VCaP
22Rv1

MSKPCa3

MSKEF1

MSKPCa2

PDX16bPDX16a

C4-2

MSKPCa13

MSKPCa12

MSKPCa19 LNCaP

MSKPCa18MSKPCa17

PARCB6

PDX09a

PARCB3

WCM1078

MSKPCa24

WCM155

MSKPCa15

PARCB1

PARCB8

WCM1262

MSKPCa16

PDX10a

PC3

MSKPCa1

MSKPCa11

MSKPCa9

H660

UMAP for ATAC-seq data

Pearson correlation

ATAC-seq group

Sample souce

Group 1
Group 2
Group 3
Group 4

MSK organoids
WCM organoids
Cell lines
PDX
GSE118207

ATAC-seq group
Sample source

Sample name

Sample type
Organoid
Tissue

B

Fig. 1. Classification of metastatic prostate cancer into four molecular
subtypes from chromatin accessibility.(A) Top: Genomic aberrations
in the prostate oncogenome from the SU2C CRPC patient samples ( 10 )
and MSKPCa organoids. Bottom: Copy number landscape of the 15 patient-
derived organoid lines and 10 matching tumor tissues using MSK-IMPACT
sequencing data. Shades of red and blue represent extent of gain and loss.
(B) Number of mutations and fraction of copy number–altered genome
of the 10 organoids and their matching patient tumor tissues. (C)Feature


distribution of the mapped ATAC-seq peaks across all samples. (D) Correlation
heatmap based on the normalized number of reads of the top 1% variable
peaks across all samples. The ATAC-seq group and the sample source are
indicated for each sample. The colors of the four ATAC-seq groups are kept
consistent throughout the paper. (E) Unsupervised UMAP on the top 1%
variable accessible peaks across all samples. (F) Immunoblot showing the
expression of AR, SYP, and GAPDH (control) across the 35 organoids, PDXs,
and cell lines.

RESEARCH | RESEARCH ARTICLE

Free download pdf